Chemo Stability Chart AtoK 1jun2016

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART
DRUG & STRENGTH

(Storage Prior to Use,
Manufacturer,
Preservative Status)
Aldesleukin
22 million units
(1.3 mg)
(Novartis)
(F)(PFL)
no preservative1
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
1.2 mL SWI1,2
18 million unit/mL
(1.1 mg/mL)1,2
48 h F1
50 mL D5W1
48 h F1
- do not use in-line

filter1,2
- avoid bacteriostatic
water for injection or
NS due to increased
aggregation1
30 70 mcg/mL1
direct diluent against

side of vial during
reconstitution1
Less than 30 mcg/mL:

dilute in D5W
containing human
albumin 0.1%2
do not shake1
SC syringe3,4
14 d F4
**(PFL)
Alemtuzumab
30 mg/mL
(Genzyme previously
Bayer)5
(F)(PFL)
do not shake
no preservative6
N/A
filter NOT required6

30 mg/mL6
discard unused
portion6
SC syringe7
discard at the end of

the day F or RT
100 mL NS or D5W6
8 h F or RT6
**(PFL)8
100 mL NS or D5W9
8 h F or RT8
**(PFL)8
BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

Activation Date: 2 March 2006
Revised Date: 1 June 2016
1/46
- do not shake8

DRUG & STRENGTH
Manufacturer,
Amifostine
500 mg
(MedImmune)
(RT)
no preservative10
Amsacrine
75 mg/1.5 mL
(Erfa Canada)
(RT)
no preservative12
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
9.7 mL NS only10
50 mg/mL10
24 h F, 5 h RT10
2550 mL* NS only10
540 mg/mL:
24 h F, 5 h RT10
glass syringes
preferred during
reconstitution;
max. time in plastic
syringe12: 15 min
5 mg/mL12
24 h RT12
500 mL D5W12
7 d F, 48 h RT12-14
PFL12
(plastic or glass
container)12
discard unused
portion15
100-250 mL NS,
D5W15
13.5 mL supplied
diluent (L-lactic
acid)1
transfer 1.5mL from
ampoule into the
diluent vial12
Arsenic
10 mg/10 mL
(Lundbeck)
(RT)
no preservative15
N/A
1 mg/mL15
24 h RT, 48 h F15
(use filter needle to

withdraw from
ampoule)

2/46
Special
Precautions/Notes
- discard cloudy
solution11

DRUG & STRENGTH
Manufacturer,
Asparaginase
(asparaginase E. coli)
10,000 units
(CGF/EUSA)
(F)
no
preservative{[12004}}
Erwinia asparaginase
(asparaginase Erwinia
chrysanthemi)
10,000 units
(CGF/EUSA)
(F)
no preservative19
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
4 mL SWI16
2500 units/mL
3 h RT or 72 h F16
syringe
complete
administration within
3 h RT or 72 h F16
50-250 mL NS or
D5W17
complete
3 h RT16,18
glass or
polypropylene
syringe19
4 h RT19
do not shake; rotate

gently16
1-2 mL NS19
10 000-5000
units/mL
15 min RT19
do not shake; mix

gently to minimize
bubbles and contact
with stopper19

3/46
Special
Precautions/Notes
- contact with the

rubber stopper may
denature the
reconstituted drug,
creating filaments of
insoluble material; if
present, use 5
micron filter during
administration19
- do not use sterile
water for
reconstitution as the
resulting product is
not isotonic19

DRUG & STRENGTH
Manufacturer,
PEG-asparaginase see pegaspargase in
L-Z chart
(pegylated
asparaginase E. coli)
azaCITIDine
100 mg
(Celgene)
(RT)
no preservative20
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
4 mL SWI20
25 mg/mL20
8 h F, 45 min
RT20
SC syringe20
8 h F, 45 min RT20
25 mg/mL20
22 h F21,22
- discard if contains
large particles20
- re-suspend syringe
contents before
injection by
vigorously rolling
syringe between
palms20
-if cold diluent
reconstitution is used
to extend stability,
minimize exposure to
RT; ensure proper
refrigeration of
diluent, reconstituted
vial, and final
product
shake vigorously20
cold diluent
reconstitution:
4 mL SWI at 28C21,22
22 h F21,22
Refrigerated
syringes20:
allow up to 30 min
prior to
administration to
reach a
temperature of ~2025C
discard syringe if
time elapsed at RT
is greater than 30
min

4/46

DRUG & STRENGTH
Manufacturer,
BCG
81 mg
(Sanofi Pasteur)
(F)(PFL)
preservative23
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
do not shake; roll to

reconstitute23
10.5 8.7108
CFU/vial
(Connaught
strain)23
2 h F, RT23
50 mL NS23
2 h F or RT after
reconstitution23
- auxiliary label:
biohazard18
1 to 8108
CFU/vial24
2 h F (PFL)24
3 mL supplied
diluent23
**(PFL)23
record time of
reconstitution
BCG
(Tice substrain)
50 mg = 1 to 8 x 108
CFU
(Hospira/Organon)
(F)(PFL)
no preservative24
1 mL preservative
free NS for
injection24
use reconstitution
device provided
transfer from vial to

60 mL syringe, rinse
vial with another 1 mL
NS. Add rinse to
same 60 mL syringe.
qs to 50 mL with NS24
2 h F24
allow to stand for a

few minutes, then
gently swirl to
suspend24

5/46
- auxiliary label:
biohazard18
- overfill unknown
- protect from light24
- do not filter24

DRUG & STRENGTH
Manufacturer,
Bendamustine
25 mg
100 mg
(Lundbeck)
(RT)(PFL)
no preservative25
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
25 mg vial:
add 5 mL SWI25
5 mg/mL25
30 minutes25
500 mL NS25
0.2-0.6 mg/mL25
complete
24 h F, 3 h RT25
1.4-16.5 mg/mL27
48 h F, RT26-28
Special
Precautions/Notes
100 mg vial:
add 20 mL SWI25
shake well;
dissolves completely
in 5 minutes25
Bevacizumab
100 mg/4 mL
400 mg/16 mL
(Roche)
(F)(PFL)
do not shake
no preservative26
Bleomycin
15 units
(NB: dose in units only)
(Bristol)
(F)
no preservative29
N/A
25 mg/mL26
discard unused
portion26
- do not shake26
100-250 mL NS
only26,27
6 mL* NS29
2.5 units/mL
48 h F29

50 mL* NS29
24 h RT29
6/46
- no overfill30

DRUG & STRENGTH
Manufacturer,
Bleomycin
15 units
(Hospira)
(F)(PFL)
no preservative31
Bleomycin
15 units
(Fresenius Kabi)
(F)(PFL)
no preservative34
Bortezomib
3.5 mg
(Actavis)
(RT)(PFL)
no preservative35
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
6 mL* NS or SWI31
2.5 units/mL31
48 h F, 24 h RT31
50 mL* NS, SWI31
24 h RT32
6 mL NS34
2.5 units/mL34
48 h F34
50 mL NS34
24 h RT34
3.5 mL NS35
1 mg/mL35
8 h RT35
syringe35
8 h RT35

7/46
Special
Precautions/Notes
- no overfill33
- auxiliary label:
WARNING:
SUBCUTANEOUS
or INTRAVENOUS
use only. Fatal if
given by other
routes.18

DRUG & STRENGTH
Manufacturer,
Bortezomib
3.5 mg
(Janssen)
(RT)(PFL)
no preservative36
Bortezomib
3.5 mg
(Teva)
(RT)(PFL)
no preservative38
Brentuximab vedotin
50 mg
(GMD Distribution for
Seattle Genetics)
(F)(PFL)
no preservative39
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
3.5 mL NS36
1 mg/mL36
2 d RT13,37
syringe36
8 h RT36
- auxiliary label:
WARNING:
SUBCUTANEOUS
or INTRAVENOUS
use only. Fatal if
given by other
routes.18
3.5 mL NS38
1 mg/mL38
8 h RT38
syringe38
8 h RT38
- auxiliary label:
WARNING:
SUBCUTANEOUS
or INTRAVENOUS
use only. Fatal if
given by other
routes.18
10.5 mL SWI39
5 mg/mL39
24 h F39
0.4-1.8 mg/mL in NS,

D5W, Lactated
Ringers (i.e. 100-250
mL)39
24 h F39
- solution should be
clear to slightly
opalescent,
colorless, and free of
visible particulates39
Direct diluent
against side of
vial during
reconstitution39
Do NOT freeze39
Do NOT shake39

8/46

DRUG & STRENGTH
Manufacturer,
Busulfan
60 mg/10 mL
(Orphan Medical)
(F)
no preservative40
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
use 5-micron nylon

filter provided with
ampoule to
withdraw drug40
discard unused
portion40
NS or D5W (dilute in
volume 10 times the
busulfan volume to
~0.5 mg/mL)40
complete
12 h F: NS40
8 h RT: NS, D5W
1 h RT41
0.10 0.26 mg/mL

NS, D5W41
(e.g., 250 mL*)
complete
8 h RT, 48 h F41
Special
Precautions/Notes
6 mg/mL40
Cabazitaxel
60 mg/1.5 mL
(sanofi-aventis)
(RT)
no preservative41
supplied diluent:
withdraw entire
contents of diluent
vial and inject into
the concentrate
vial41
10 mg/mL41
slowly direct diluent

against inside of vial
to limit foaming41
mix by repeated
inversions for 45
sec41
do NOT shake41
let sit for 5 min41

9/46
- concentrate and
diluent vials contain
overfill41
- use non-DEHP bag
and tubing41
- use 0.22 micron inline filter41
- diluent contains
13% (w/w) ethanol in
water41
- discard if
crystallization
occurs41

DRUG & STRENGTH
Manufacturer,
CARBOplatin
50 mg/5 mL
150 mg/15 mL
450 mg/45 mL
(Accord)
(RT)(PFL)
no preservative42
CARBOplatin
50 mg/5 mL
150 mg/15 mL
450 mg/45 mL
600 mg/60 mL
(Hospira)
(RT)(PFL)
no preservative43
CARBOplatin
50 mg/5 mL
150 mg/15 mL
450 mg/45 mL
(Teva/Novopharm)
(RT)(PFL)
no preservative46
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
10 mg/mL42
discard unused
portion42
0.5-10 mg/mL42
8 h RT, 24 h F42
- do NOT use
aluminum-containing
needle, syringe, or
tubing42
discard unused
portion43
0.3-10 mg/mL44
24 h RT,45 48 h F43
- do NOT use
aluminum-containing
needle, syringe, or
tubing44
discard unused
portion RT46
0.5-10 mg/mL47
8 h RT46
- do NOT use
aluminum-containing
needle, syringe, or
tubing46
N/A
N/A
10 mg/mL43
10 mg/mL46

NS, D5W42
NS, D5W11,43
NS, D5W11,46,48
10/46

DRUG & STRENGTH
Manufacturer,
Carfilzomib
60 mg
(Amgen)
(F)(PFL)
no preservative49
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
29 mL SWI49
2 mg/mL49
24 h F, 4 h RT49
50 100 mL D5W
only49
do NOT dilute in NS49
complete
24 h F, 4 h RT after
reconstitution49
- infusion lines may

be flushed with
either NS or D5W49
glass50 or polyolefin
container11
24 h F: in glass50 or
polyolefin container11
500 mL NS or D5W50
- do not use if
product has oily
droplets50
use within 4 h of
reconstitution RT50
swirl gently; do not

shake to avoid foam
formation49
if foaming occurs,
allow to settle until
clear (~5 minutes)49
record time of
reconstitution
Carmustine
100 mg
(Bristol Labs)
(F)
no preservative50
3 mL diluent
(supplied)50
3.3 mg/mL in 10%

ethanol50
24 h F, 8 h RT50
diluent to reach RT,

then dissolve drug
with 3 mL diluent;
add 27 mL SWI50
record time of
reconstitution

11/46

DRUG & STRENGTH
Manufacturer,
Cetuximab
100 mg/50 mL
200 mg/100 mL
(ImClone/BMS)
(F)
do not dilute
do not shake
no preservative51
CISplatin
10 mg/10 mL
50 mg/50 mL
100 mg/100mL
(Hospira)
(RT)(PFL)
no preservative52
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
2 mg/mL51
discard unused
portion after 12 h
F, 8 h RT51
syringe51
12 h F, 8 h RT51
sterile evacuated
container or bag e.g.
polyolefin,
polyethylene,
ethylene vinyl
acetate, DEHP
plasticized PVC, PVC
bag, or glass51
12 h F, 8 h RT51
- administer with a
0.2 or 0.22 micron
low protein binding
in-line filter51
- normal saline may
be used to flush the
line51
- solution may
contain white
particulates which do
not affect product
quality51
Less than or equal to

60 mg: 100 mL* NS
48 h RT53
N/A
1 mg/mL52
48 h RT53
Greater than 60 mg:

250 mL* NS
500 or 1000 mL* NS,
D5-NS, D5-1/2S, D5NS with mannitol, D51/2S with
mannitol52,54; D5W1/3S with mannitol52

12/46
- do NOT use
aluminum-containing
needle, syringe or
tubing52

DRUG & STRENGTH
Manufacturer,
CISplatin
10 mg/10 mL
50 mg/50 mL
100 mg/100mL
(Sandoz)
(RT)(PFL)
no preservative55
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
1 mg/mL55
48 h RT55,56

60 mg: 100 mL NS*
24 h RT55
- do NOT use
aluminum-containing
needle, syringe or
tubing55
24 h RT58
- do NOT use
aluminum-containing
needle, syringe or
tubing58
Greater than 60 mg:

250 mL NS*
NS; 0.45 % Sodium
Chloride with or
without mannitol57
2 L of D5 in one-half
or one-third NS
containing 37.5 g of
mannitol55
CISplatin
10 mg/10 mL
50 mg/50 mL
100 mg/100mL
(Teva)
(RT)(PFL)
no preservative58
N/A
1 mg/mL58
discard unused
portion18

60 mg: 100 mL* NS
Greater than 60 mg:
250 mL* NS
2 L of D5 in one-half
or one-third NS
containing 37.5 g of
mannitol58

13/46

DRUG & STRENGTH
Manufacturer,
Cladribine
10 mg/10 mL
(Janssen-Ortho)
(F)(PFL)
no preservative59
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
1 mg/mL59
discard unused
portion59
SC syringe60
48h F, end of day

RT13,59,61,62
500 mL NS only59
- shake vigorously to
dissolve any
precipitates from
refrigeration59
24 h RT59
Do NOT use D5W59

Cassette:
qs to 100 mL with
bacteriostatic NS
only via SIMS
DELTEC INC.
MEDICATION
CASSETTES59 filter
drug and diluent
through 0.22 micron
filter as each solution
is being introduced
into the cassette

at least 7 days59
14/46

DRUG & STRENGTH
Manufacturer,
Cladribine
10 mg/10 mL
(Fresenius Kabi)
(F)(PFL)
no preservative63
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
1 mg/mL63
discard unused
potion63
SC syringe60
discard end of
day13,62,63
500 mL NS only
24 h RT
Do NOT use D5W
Clodronate
300 mg/10 mL
(Oryx)
(RT)
no preservative64
N/A
30 mg/mL64
discard unused
portion64

Cassette:
qs to 100 mL with
bacteriostatic NS
only via SIMS
DELTEC INC.
MEDICATION
CASSETTES63 filter
drug and diluent
through 0.22 micron
filter as each solution
is being introduced
into the cassette
at least 7 days63
500 mL NS or D5W64
12 h RT64
15/46
Special
Precautions/Notes

DRUG & STRENGTH
Manufacturer,
Cyclophosphamide
200 mg
500 mg
1000 mg
2000 mg
(Baxter)
(RT)(PFL)
no preservative65
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
NS66
20 mg/mL65
48 h F,56,65,67
24 h RT65

1 g: 100 mL NS*
72 h F,65,67
24 h RT65
200 mg: 10 mL
500 mg: 25 mL
1000 mg: 50 mL
2000 mg: 100 mL65
Special
Precautions/Notes
Greater than 1 g: 250

mL NS*
high dose in BMT:
may need 500 NS*
NS, D5W, D5NS65
Cytarabine
100 mg/1 mL
1000 mg/10mL
2000 mg/20mL
(Hospira)
(RT)(PFL)
no preservative68
N/A
100 mg/mL68
24 h RT68
record time of
puncture

100 mL* NS, Water

for Injection, D5W,
Lactated Ringers68
72 h F, 24 h RT from
initial vial puncture68
16/46
- do not use for IT

injection

DRUG & STRENGTH
Manufacturer,
Cytarabine
IT injection
100 mg/1 mL
1000 mg/10mL
2000 mg/20mL
(Hospira)
(RT)(PFL)
no preservative68
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
100 mg/mL68
24 h RT68
diluents containing
preservatives should
NOT be used for
intrathecal
administration68
use within 4 h of
- auxiliary label: IT
injection18
- label to include
route in full (i.e.,
INTRATHECAL
injection) attached to
both syringe and
outer ziplock bag18
record time of
puncture
qs to 6 mL with
preservative free NS69
Cytarabine
SC injection
100 mg/1 mL
1000 mg/10mL
2000 mg/20mL
(Hospira)
(RT)(PFL)
no preservative68
record time of
puncture
Dacarbazine
100 mg
200 mg
(Abraxis)
(F)(PFL)
no preservative71
100 mg: 9.9 mL

SWI71
200 mg: 19.7 mL
SWI71
N/A
100 mg/mL68
24 h RT68
syringe
14 d F, 48 h RT18,70
- do not use for IT

injection
10 mg/mL71
72 h F, 8 h RT71
250-1000 mL* NS or
D5W
24 h F, 8 h RT71
- protect container
from light during
storage and
administration72
- overfill unknown

**(PFL)11,71
see Special
Precautions/Notes
Column
17/46

DRUG & STRENGTH
Manufacturer,
Dacarbazine
200 mg
600 mg
(Hospira)
(F)(PFL)
no preservative73
DACTINomycin
0.5 mg
(GMD Pharma for
Recordati)
(RT)(PFL)
no preservative75
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
200 mg: 19.7 mL

SWI73
600 mg: 59.1 mL
SWI73
10 mg/mL73
48 h F, 8 h RT73
0.193.0 mg/mL13,73
24 h F73
(PFL)74
250-1000 mL* NS or
D5W
**(PFL)72
see Special
Precautions/Notes
Column
1.1 mL SWI
(preservative-free)75
0.5 mg/mL
(500 mcg/mL)75
discard at end of
day56
syringe75
use within 4 h of
Do NOT use SWI

with preservative
(may form
precipitate)75
10 mcg/mL or
greater75
NS, D5W75,76

18/46
Special
Precautions/Notes
- protect container
from light during
storage and
administration72
- no overfill33,74
- drug loss reported

with some cellulose
ester membrane inline filters75

DRUG & STRENGTH
Manufacturer,
Daratumumab
100mg/5mL
400mg/20mL
(Jannsen)
(F)(PFL)
do not shake
no preservative77
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
20 mg/mL77
discard unused
portion77
500-1000 mL NS
dilute to final volume
by withdrawing
volume from bag
equal to volume of
drug to be added77
24 h F, followed by
15 h infusion (total 39
h)77
- administer with a
0.22 or 0.2 micron
low protein binding
in-line filter77
- discard if visible
particles are
observed77
- complete infusion
within 15 hours77
mix by gentle
inversion77
DAUNOrubicin
20 mg
(Erfa Canada Inc.)78
(RT)(PFL)79
no preservative80
DAUNOrubicin
20 mg
(Teva/Novopharm)
(RT)(PFL)
no preservative82
4 mL SWI78
5 mg/mL78,81
48 h F, 24 h RT80
100-250 mL in
isotonic solution e.g.,
NS78
allow bag to come to

room temperature,
then use
immediately77
24 h RT, 48 h F78
no data for D5W80

4 mL SWI82
5 mg/mL82
24 h RT, 48 h F82
(PFL)82

100-250 mL
NS or D5W11
48 h F, 24 h RT82
**(PFL)82
19/46

DRUG & STRENGTH
Manufacturer,
Degarelix
80 mg
120 mg
(Ferring)
(RT)
do not shake83
no preservative84
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
80 mg: 4.2 mL SWI

(supplied diluent)83
20 mg/mL83
2 h RT83
SC syringe83
2 h RT83
120 mg: 3 mL SWI

(supplied diluent)83
40 mg/mL83
swirl gently; avoid

shaking to prevent
foam formation83
reconstitution may
take up to 15 min83

20/46
Special
Precautions/Notes

DRUG & STRENGTH
Manufacturer,
Denosumab
(XGEVA)
120 mg/1.7 mL
(Amgen)
(F)(PFL)
do not shake
no preservative85
Dexrazoxane
250 mg
500 mg
(Pfizer)
(RT)
no preservative86
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
71 mg/mL85
discard unused
portion56,85
SC syringe85
use within 4 h of
initial puncture56
SWI86
10 mg/mL86
30 min RT, 4 h
F86
MUST BE FURTHER
DILUTED With
Lactated Ringers
Injection to 1.3 3.0
mg/mL86
1 h RT, 4 h F86
250 mg: 25 mL
500 mg: 50 mL

21/46
Special
Precautions/Notes
- not interchangeable
with PROLIA85
- do not use if
solution is cloudy;
trace amounts of
translucent to white
proteinaceous
particles are
acceptable85
- avoid vigorous
shaking85
- bring to room
temperature 15-30
minutes prior to
administration85

DRUG & STRENGTH
Manufacturer,
DOCEtaxel
20 mg/2 mL
80 mg/8 mL
160 mg/16 mL
(Hospira)
(F, RT)(PFL)
preservative87
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
10 mg/mL87
20mg/2 mL vial:
discard unused
portion18,87
0.3-0.74 mg/mL87
complete
4 h F,87 48 h RT18,88
(250 mL NS or
D5W)87
80 mg/8 mL or
160 mg/16 mL
vial (maximum
number of
punctures: up to 3
doses can be
removed when a
venting needle is
also inserted, i.e.,
6 punctures
total)90
14 d F18,87
**(PFL)18,87

22/46
Special
Precautions/Notes
- use non-DEHP bag

and IV administration
set87
- do not use chemo
dispensing pins89

DRUG & STRENGTH
Manufacturer,
DOCEtaxel
20 mg/0.5 mL
80 mg/2 mL
(sanofi-aventis)
(F, RT)(PFL)
no preservative91
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
supplied diluent :
- if vials were
refrigerated, allow to
warm for 5 min at
RT. Withdraw entire
contents of the
diluent and inject the
entire contents of
the syringe into the
corresponding
concentrate vial. Mix
by repeated
inversions for 45
sec91
10 mg/mL91
48 h F, RT18,91,92
0.3-0.74 mg/mL91
complete
4 h F,91
48 h RT18,92
- use non-DEHP
bag and IV
administration set91
24 h F, RT from initial
vial puncture93
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
(250 mL NS or
D5W)91
DO NOT SHAKE91
Let sit for 5
minutes91
DOXOrubicin
10 mg/5 mL
20 mg/10 mL
50 mg/25 mL
200 mg/100 mL
(Accord)
(F)(PFL)
no preservative93
N/A
2 mg/mL93
8 h93

syringe93
23/46

DRUG & STRENGTH
Manufacturer,
DOXOrubicin
10 mg
50 mg
150 mg
(Hospira)
(RT)(PFL)
no preservative94
DOXOrubicin
10 mg/5 mL
20 mg/10 mL
50 mg/25 mL
200 mg/100 mL
(Teva/Novopharm)
(F)(PFL)
no preservative96
DOXOrubicin
10 mg/5 mL
50 mg/25 mL
200 mg/100 mL
(Pfizer)
(F)
no preservative97
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
NS, SWI, D5W94

(NS reconstitution
takes longer)
10 mg: 5 mL
50 mg: 25 mL
150 mg: 75 mL
2 mg/mL94
48 h F, 24 h
RT13,94
syringe94
48 h F, 24 h RT13,95
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
N/A
2 mg/mL96
8 h96
syringe96
48 h F, 24 h RT96
from initial vial
puncture
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
2 mg/mL97
discard unused
portion56,97
syringe97
48 h F, 24 h RT97
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
record time of
puncture
N/A

24/46

DRUG & STRENGTH
Manufacturer,
DOXOrubicin
Pegylated Liposomal
20 mg/10 mL
(Janssen)
(F)
no preservative98
Epirubicin
10 mg/5 mL
20 mg/10 mL
50 mg/25 mL
150 mg/75 mL
200 mg/100 mL
(Novopharm)
(F)(PFL)
no preservative99
Epirubicin
10 mg/5 mL
50 mg/25 mL
200 mg/100 mL
(Fresenius Kabi)
(F)(PFL)
no preservative100
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
2 mg/mL98
discard unused
portion98
Less than 90 mg: 250

mL D5W only98
24 h F98
Greater than or equal

to 90 mg: 500mL
D5W only98
N/A
2 mg/mL99
8 h F, RT99
syringe99
48 h F, 24 h RT
from initial vial
puncture99
N/A
2 mg/mL100
8 h100
syringe100
48 h F, 24 h RT
from initial vial
puncture100
100 mL* NS or D5W
2 d F, RT:
NS or D5W18,100
record time of
puncture

25/46
Special
Precautions/Notes
- do not filter98

DRUG & STRENGTH
Manufacturer,
Epirubicin
10 mg/5 mL
50 mg/25 mL
200 mg/100 mL
(Pfizer)
(F)(PFL)
no preservative101
EPOCHR
(ULYEPOCHR protocol)
(RT)(PFL)
no preservative18,102-105
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
2 mg/mL101
8 h101
syringe101
48 h F, 24 h RT from
100 mL* NS or D5W11
2 d F, RT: NS or
D5W53
etoposide dose
125 mg/24 h:
in 500 mL NS
etoposide
concentration
0.25 mg/mL:
complete
72 h RT
record time of
puncture
see brand specific

entries for:
DOXOrubicin as
applicable
see brand specific

entries for:
DOXOrubicin,
etoposide,
vinCRIStine
see brand
specific entries
for: DOXOrubicin,
etoposide,
vinCRIStine
etoposide dose
>125 mg/24 h:
in 1000 mL NS
precipitation occurs
at etoposide
concentrations
>0.25 mg/mL
**(PFL)
see Special
Precautions/Notes
column

26/46
Special
Precautions/Notes
- final product is a
3-in-1 solution
containing
etoposide,
DOXOrubicin,
vinCRIStine (refer to
ULYEPOCHR
protocol)
- use non-DEHP bag
and tubing only
- use inline filter
- protect container
from light during
administration and
storage

DRUG & STRENGTH
Manufacturer,
eriBULin
1 mg/2 mL
(Eisai Limited)
(RT)(PFL)106
no preservative18
Etoposide
100 mg/5 mL
500 mg/25 mL
1000 mg/50 mL
(BMS)
(RT)
preservative107
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
0.5 mg/mL106
discard at end of
day18,106
IV syringe106
24 h F, 6 h RT106
- do not administer
through dextrose
containing lines106
- vials contain
dehydrated alcohol
USP (5% v/v)106
N/A
20 mg/mL107
14 d RT11,13,108-110
0.2-0.4 mg/mL107
0.2 mg/mL:
48 h RT13,107

500 mL* NS or
D5W107
0.4 mg/mL:
24 h RT107
27/46
- use non-DEHP bag

and tubing only
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)

DRUG & STRENGTH
Manufacturer,
Etoposide
100 mg/5 mL
200 mg/10 mL
500 mg/25 mL
1000 mg/50 mL
(Sandoz)
(RT)(PFL)
preservative112
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
20 mg/mL112
14 d RT112
0.2-0.4 mg/mL NS,

D5W112
0.2 mg/mL:
7 d F, RT112
500 mL* NS or D5W
0.4 mg/mL:
12 h F, RT112
- use non-DEHP bag

and tubing only
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)

28/46

DRUG & STRENGTH
Manufacturer,
Etoposide
100 mg/5 mL
200 mg/10 mL
500 mg/25 mL
1000 mg/50 mL
(Teva/Novopharm)
(RT)(PFL)
no preservative113
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
20 mg/mL113
discard unused
portion113
NS
0.2-0.3 mg/mL:
7 d F,114 2 d RT114,115
- use non-DEHP bag

and tubing only
- for ULYEPOCHR
protocol, see entry
for EPOCHR
(3-in-1solution
containing
etoposide,
DOXOrubicin,
vinCRIStine)
Stability is
concentration
dependent
0.4-0.5 mg/mL:
1 d F,114 1d RT114
0.6-9.0mg/mL:
generally unstable
9.5 mg/mL:
2 d F,114 1d RT114
10-12 mg/mL:
7 d F,114 2 d RT114,115
Etoposide phosphate
(ETOPOPHOS)
100 mg
(BMS)
(F)(PFL)
no preservative117
5 mL NS, D5W,
SWI, BWI117,118
20 mg/mL117,118
10 mL NS, D5W,
SWI, BWI117,118
10 mg/mL117,118
24 h RT117,118, 48
h F18,117,118

D5W113
4 h RT113,116
500 mL* NS,

D5W117,118
24 h F, RT117,118
(do not dilute to less

than 0.1 mg/mL)117,118
29/46

DRUG & STRENGTH
Manufacturer,
Filgrastim
(NEUPOGEN)
300 mcg/1 mL
480 mcg/1.6 mL
(Amgen)
(F)(PFL)
do not shake
no preservative119
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
300 mcg/mL119
discard unused
portion18
SC syringe119
14 d F18,120
50-100 mL D5W
only121
48 h RT, 7 d F18,120
- albumin is added to
D5W to prevent
filgrastim adsorption
to plastic119
- incompatible with
saline119,121
- do NOT dilute to
less than 5
mcg/mL119
in PVC, polyolefin, or
glass119
(for filgrastim
concentrations of 515 mcg/mL in D5W,
add albumin 2
mg/mL)119
Fludarabine
50 mg
(Berlex)
(F)
no preservative122
Fludarabine
50 mg
(Teva/Novopharm)
(F)
no preservative124
2 mL SWI122
25 mg/mL122
48 h F or RT13,53
dilute to maximum of
1 mg/mL122,123
48 h F, RT13,53
50-100 mL* NS or
D5W122
N/A
25 mg/mL124
discard unused
portion124

dilute to maximum of
1 mg/mL124
48 h F, 24 h RT124
50-100 mL* NS or
D5W
30/46

DRUG & STRENGTH
Manufacturer,
Fluorouracil
5000 mg/100 mL
(Accord)
(RT)(PFL)
no preservative125
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
50 mg/mL125
8 h RT125
syringe125
8 h RT125
2 mg/mL in D5W125
24 h RT125
50-1000 mL* D5W
Fluorouracil
5000 mg/100 mL
(Hospira)
(RT)(PFL)
no preservative129
N/A
50 mg/mL129
8 h RT126,129
CIVI: ambulatory
pump126
complete within
8 d127,128
syringe13
48 h RT13,28,126
2-10 mg/mL in
D5W126,129
24 h RT126,129
50-1000 mL* D5W

CIVI: ambulatory
pump126

complete within
8 d11,13,127,128
31/46
Special
Precautions/Notes

DRUG & STRENGTH
Manufacturer,
Fluorouracil
500 mg/10 mL
5000 mg/100 mL
(Sandoz)
(RT)(PFL)
no preservative130
Gemcitabine
200 mg
1000 mg
2000 mg
(Accord)
(RT)
no preservative131
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
50 mg/mL130
4 h RT18
syringe
4 h RT18
D5W130
24 h RT130
CIVI: ambulatory
pump126
complete within
8 d11,13,127,128
0.1-10 mg/mL NS131
48 h RT18,132,133
200 mg: 5 mL NS
1000 mg: 25 mL NS
2000 mg: 50 mL
NS131
38 mg/mL131
24 h RT131

32/46
Special
Precautions/Notes

DRUG & STRENGTH
Manufacturer,
Gemcitabine
200 mg
1000 mg
(Eli-Lilly)
(RT)
no preservative134
Gemcitabine
200 mg
1000 mg
2000 mg
(Hospira)
(F)
no preservative136
Gemcitabine
200 mg
1000 mg
2000 mg
(Hospira)
(RT)137
no preservative138
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
200 mg: 5 mL NS
1000 mg: 25 mL
NS134
38 mg/mL134
48 h RT134,135
syringe134
48 h RT13,134,135
0.110 mg/mL
NS134,135
48 h F, RT13,134,135
N/A
38 mg/mL136
discard unused
portion at the end
of the day136
0.1 38 mg/mL NS,

D5W136
24 h RT136
200 mg: 5 mL NS
1000 mg: 25 mL NS
2000 mg: 50 mL
NS137
38 mg/mL137
48 RT56,137,139
syringe137
24 h RT137,139
0.1 - 26 mg/mL
NS137,139
48 h RT56,139

33/46
Special
Precautions/Notes

DRUG & STRENGTH
Manufacturer,
Gemcitabine
200 mg
1000 mg
(Teva/Novopharm)
(RT)
no preservative140
Gemcitabine
200 mg
1000 mg
(Sandoz Standard)
(RT)
no preservative141
IDArubicin
5 mg
10mg
(Pfizer)
(RT)(PFL)
no preservative146
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
200 mg: 5mL NS

1000 mg: 25 mL
NS140
38 mg/mL140
24 h RT140
0.1 - 38 mg/mL NS140
24 RT140
200 mg: 5 mL NS
1000 mg: 25 mL
NS141
38 mg/mL141
48 h RT141,142
syringe141
48 h RT141-143
0.1 - 38 mg/mL NS or
D5W141,144
48 h RT13,145
syringe146
48 h F, 24 h RT146
5 mg: 5 mL SWI146
10 mg: 10 mL
SWI146
1 mg/mL146
48 h F,
24 h RT146
**(PFL)146
vial contents under

negative pressure146
do NOT use BWI to
reconstitute146

34/46
Special
Precautions/Notes
- avoid alkaline
solutions146

DRUG & STRENGTH
Manufacturer,
IDArubicin PFS
5 mg/5 mL
10 mg/10 mL
20 mg/20 mL
(Pfizer)
(F)(PFL)
no preservative146
IDArubicin
5 mg/5 mL
10 mg/10 mL
20 mg/20 mL
(Fresenius Kabi)
(F)(PFL)
no preservative147
Ifosfamide
1000 mg
3000 mg
(Baxter)
(RT)
no preservative148
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
1 mg/mL146
24 h RT,
48 h F
syringe146
4 h from initial
puncture18
- avoid alkaline
solutions146
- avoid alkaline
solutions147
**(PFL)146
N/A
1 mg/mL147
discard unused
solution147
syringe147
4 h from initial
puncture18
1000 mg: 20 mL
SWI148
50 mg/mL148
24 h RT, 48 h
F18,148
0.620 mg/mL148
24 h RT, 72 h F148
5001000 mL* NS,

D5W, Lactated
Ringers148
24 h F, RT when
mixed with mesna11
3000 mg: 60 mL
SWI148
shake well

35/46

DRUG & STRENGTH
Manufacturer,
Ifosfamide
1000 mg
3000 mg
(Fresenius Kabi)
(RT)
no preservative149
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
1000 mg: 20 mL
SWI
3000 mg: 60 mL
SWI149
50 mg/mL149
24 h RT, 48 h
F18,149
0.6-20 mg/mL149
24 h RT, 72 h F149
500-1000 mL* NS
D5W, Lactated
Ringers149
shake well
Iniparib
100 mg/10 mL
(sanofi-aventis)
(F)
no preservative150
Interferon Alfa -2b

10 million units/1 mL
(Merck)
(F)
preservative151,152
N/A
10 mg/mL150
discard unused
portion150
24 h F, RT when
mixed with mesna11
24 h RT150
- *may also use

empty IV bag and qs
to final volume of
250 mL with NS,
D5W150
syringe151
7 d F18
final concentration
0.3 million IU/mL151
24 h F, RT151
- vials can be kept at

RT for up to 7 days
before use; discard if
not used within this
time151
250 mL NS, D5W

dilute to 250 mL final
volume by
withdrawing volume
from bag equal to
volume of drug to be
added*150
N/A
10 million
units/mL151
7 d F151
50 mL NS151

Special
Precautions/Notes
36/46

DRUG & STRENGTH
Manufacturer,
Interferon Alfa -2b
18 million units/3 mL
(Merck)
(F)
preservative151,152
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
6 million
units/mL151
14 d F18,151
syringe151
14 d F18,152
final concentration
24 h F, RT151

RT for up to 7 days
time151
50 mL NS151
Interferon Alfa -2b
25 million units/2.5 mL
(Merck)
(F)
preservative151,152
N/A
10 million
units/mL151
14 d F18,151
syringe151
14 d F18,152
final concentration
24 h F, RT151
50 mL NS151

37/46

RT for up to 7 days
time151

DRUG & STRENGTH
Manufacturer,
Interferon Alfa -2b
10 million units
(Merck)
(F)
no preservative (unless
reconstituted with
BWI)151
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
1 mL supplied
diluent (SWI)151
10 million
units/mL151
24 h F151
syringe151
24 h F18,152
final concentration
24 h F, RT152
- after reconstitution,
provides an isotonic
solution which may
be used for
intralesional
injection151
- non-reconstituted
vials can be kept at
RT for up to 4 weeks
not reconstituted for
use within this
time151

reconstitute151
100 mL NS151
1 mL BWI151
14 d F18,151
syringe151
14 d F18,151
final concentration
24 h F, RT152

reconstitute151
100 mL NS151

38/46

DRUG & STRENGTH
Manufacturer,
Interferon Alfa -2b
18 million units
(Merck)
(F)
no preservative (unless
reconstituted with
BWI)151
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
1 mL supplied
diluent151
18 million
units/mL151
24 h F151
syringe151
24 h F18,152
final concentration
> 0.1 million IU/mL151
24 h F, RT152
- non-reconstituted
vials can be kept at
RT for up to 4 weeks
not reconstituted for
use within this
time151

reconstitute151
100 mL NS151
1 mL BWI151
14 d F18,151

reconstitute151
syringe151
14 d F18,151
final concentration
> 0.1 million IU/mL151
24 h F, RT152
100 mL NS151

39/46

DRUG & STRENGTH
Manufacturer,
Ipilimumab
50 mg/10 mL
200 mg/40 mL
(BMS Canada)
(F)(PFL)
no preservative153
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
N/A
5 mg/mL153
24 h F,RT153
1 4 mg/mL in
NS, D5W 100 mL153
24 h F,RT153
OR
undiluted in empty
viaflex bag or glass
bottle
(allow vials to stand at
RT for ~5 min prior to
withdrawal of
contents)153
Irinotecan
40 mg/2 mL
100 mg/5 mL
500 mg/25 mL
(Accord)
(RT)(PFL)
no preservative154
N/A
20 mg/mL154
discard unused
portion154

0.12 2.8 mg/mL154
48 h F, 24 h RT
500 mL*
D5W (preferred),
NS154
**(PFL)154
40/46
Special
Precautions/Notes
- do NOT shake153
- administer with 0.2
or 0.22 low protein
binding in-line filter153
- vials may contain
translucent-to-white
amorphous
particles153
- discard if cloudy or
has pronounced
colour change
(should be clear to
pale yellow)153
- flush line with NS or
D5W after infusion153

DRUG & STRENGTH
Manufacturer,
Irinotecan
40 mg/2 mL
100 mg/5 mL
500 mg/25 mL
(Hospira)
(RT)(PFL)
no preservative155
Irinotecan
40 mg/2 mL
100 mg/5 mL
(Pfizer)
(RT)(PFL)
no preservative158
Irinotecan
40 mg/2 mL
100 mg/5 mL
500 mg/25 mL
(Sandoz)
(RT)(PFL)
no preservative159
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
N/A
20 mg/mL155
2 days RT13,156,157
0.12 2.8 mg/mL155
24 h RT: D5W, NS155
500 mL11 D5W

(preferred), NS155
- do NOT refrigerate
if in NS158
48 h F: D5W
0.12 2.8 mg/mL158
24 h RT: D5W, NS158
500 mL11 D5W

(preferred), NS158
48 h F: D5W
0.12-2.8 mg/mL159
24 h RT: D5W, NS159
D5W (recommended),
NS159
48 h F: D5W159
N/A
N/A
20 mg/mL158
20 mg/mL159
discard unused
portion158
discard unused
portion56,159

**(PFL)155
**(PFL)158
**(PFL)159
41/46
- do NOT refrigerate
if in NS158

DRUG & STRENGTH
Manufacturer,
Ixabepilone
15 mg
(contains 16 mg)
45 mg
(contains 47 mg)
(BMS)
(F)(PFL)
no preservative160
Reconstitute
With:
To Give:
Vial
Stability
Product
Product Stability
Special
Precautions/Notes
15 mg: 8 mL
supplied diluent160
2 mg/mL160
1 h RT160
0.2 0.6 mg/mL in

Lactated Ringers
Injection USP (use
non-DEHP infusion
container)160
6 h RT160
- use 0.2-1.2 micron

in-line filter160
- use non-DEHP bag
and administration
set160
45 mg: 23.5 mL
supplied diluent160
* Suggested volume based on usual dose range and any concentration range of stability data
** Protect from light means minimizing exposure to direct sunlight over a storage period. More specific information on protection from light (eg, protecting container and tubing during
administration) will be indicated in the Special Precautions/Notes column.
Centres are not to change the content locally but should forward suggestions to the Cancer Drug Manual staff.
Explanatory Notes
Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP
28,161
797.
Vial stability: Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize growth of microorganisms).
Discard unused portion: Unused portion from single use vials should be discarded at the end of the day.
overfill known is stated if the manufacturer states overfill that is present is within acceptable limits.
Complete administration within __ is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation, usually including entire
time required for preparation (from first puncture), storage, and administration of infusion.
Abbreviations
BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
D5W = dextrose 5% in water
F = refrigerate
Non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
NS = normal saline
PFL = protect from light
RT = room temperature
SWI = sterile water for injection

42/46
References
1. Novartis Pharmaceuticals Canada Inc. PROLEUKIN product monograph. Dorval, Quebec; 6 July 2006.
2. McEvoy GK, editor. AHFS 2008 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc. p. 917-925.
3. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and Regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055-2066.
4. Koreth J, Alyea EP, Cutler C, Ho VT, Antin JH, Soiffer RJ, et al. Clinical Study Protocol: A phase I study of ultra-low dose subcutaneous interleukin-2 (IL-2) for treatment of refractory
chronic graft versus host disease. : Dana-Farber Cancer Institute; 14 Dec 2010.
5. Rui Paiva. Personal communication. Business Unit Director, Transplant and Oncology; 1 June 2009.
6. Bayer HealthCare Pharmaceuticals. MabCampath Package Insert. Toronto, Ontario; 1 September 2007.
7. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as
first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004(18):484-490.
8. Berlex Canada Inc. Campath Drug Information. San Antonio, Texas; undated.
9. Schering AG. MABCAMPATH Package Leaflet. Berlin, Germany; April 2002.
10. MedImmune Pharma B.V. Ethyol Package Insert. The Netherlands; 2003.
11. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2005.
12. Erfa Canada Inc. AMSA PD injection product monograph. Westmount, Quebec; 16 August 2005.
13. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 January 2006.
14. Tanya Leduc. Personal communication. Acting editor, BC Cancer Agency Cancer Drug Manual; 2 June 2008.
15. Lundbeck Canada Inc. TRISENOX product monograph. Montreal, Quebec; 6 June 2013.
16. CGF Pharmatec for EUSA Pharma. KIDROLASE product monograph. Montreal, Quebec; 17 April 2008.
17. Lexi-Drugs (database on the Internet). Asparaginase (E. coli). Lexi-Comp Inc., 1 July 2015. Available at: http://online.lexi.com. Accessed 25 August 2015.
18. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
19. CGF Pharmatec for EUSA Pharma. ERWINASE for Injection product monograph. Montreal, Quebec; 19 February 2015.
20. Celgene Inc. VIDAZA product monograph. Mississauga, Ontario; 17 May 2012.
21. Tutino A, Lai M. Cold water reconstitution of Vidaza with subsequent refrigerated storage prolongs drug stability. Eur J Oncol Pharm 2011;5(3-4):24-25, 34.
22. Celgene Corporation. VIDAZA full prescribing information. Summit, NJ, USA; December 2012.
23. Repchinsky C editor. ImmuCyst monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario; 2005.
24. Organon Canada Ltd. OncoTICE Product Monograph. Scarborough, Ontario; 24 October 2001.
25. Lundbeck Canada Inc. TREANDA product monograph. Montreal, Quebec; 22 August 2012.
26. Roche. Bevacizumab for injection, Summary product information. Mississauga, Ontario; 2005.
27. Hoffmann-La Roche Limited. Ro 4876647 Avastin Investigator's Brochure. Mississauga, Ontario; 14th edition, November 2006.
28. The United States Pharmacopeia (USP). General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States
Pharmacopeial Convention, Inc.; 2004.
29. Repchinsky C editor. Blenoxane monograph, Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario; 2005.
30. Catherine Dehaut M.Sc. Personal communication. Medical Information Associate, Bristol Laboratories of Canada; February 2008.
31. Faulding (Canada) Inc. Bleomycin Product Monograph. Montreal, Quebec; 3 June 2002.
32. Sheila Ahmed. Personal communication Bleomycin. Regulatory Affairs Associate, Bleomycin, Mayne Pharma Canada. Ref JUN-128-2004; July 2, 2004.
33. Robert Caunce. Personal communication. Quality System Manager, Hospira Australia; 12 March 2008.
34. Pharmaceutical Partners of Canada Inc. Bleomycin For Injection product monograph. Richmond Hill, Ontario; 14 January 2008.
35. Actavis Pharma Company. ACT BORTEZOMIB Bortezomib for injection product monograph. Mississauga, Ontario; 24 September 2015.
36. Janssen Inc. VELCADE product monograph. Toronto, Ontario; 20 June 2013.
37. Walker S, Milliken D, Law S. Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4C and room temperature (23C). Canadian Journal of Hospital Pharmacy
2006;59 (Suppl 1):62.
38. Teva Canada Limited. Bortezomib for injection product monograph. Toronto, Ontario; 22 January 2015.
39. GMD Distribution Inc. for Seattle Genetics Inc. ADCETRIS product monograph. Oakville, Ontario; 1 February 2013.

43/46
40. Orphan Medical Inc. Busulfex Package Insert. Flamborough, Ontario; August 1999.
41. sanofi-aventis Canada Inc. JEVTANA product monograph. Laval, Quebec; 13 September 2013.
42. Accord Healthcare Inc. Carboplatin injection product monograph. Markham, Ontario; 15 December 2015.
43. Mayne Pharma (Canada) Inc. Carboplatin Package Insert. Montreal, QC; Undated.
44. Nancy Grigoriadis. Personal communication. Regulatory Affairs Associate, Mayne Pharma (Canada) Inc. 2 October 2006.
45. Nancy Grigoriadis. Personal communication. Regulatory Affairs Associate, Mayne Pharma (Canada) Inc. 2 October 2006.
46. Novopharm Limited. Carboplatin Package Insert. Toronto, Canada; Undated.
47. Manjinder S Kang. Personal communication. Regulatory Affairs Drug Information Pharmacist, Novopharm Canada. 14 March 2005.
48. Repchinsky C editor. Paraplatin-AQ, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
49. Amgen Canada Inc. KYPROLIS product monograph. Mississauga, Ontario; 15 January 2016.
50. Bristol Laboratories of Canada. BiCNU Package Insert. Montreal, Canada; 2002.
51. ImClone Systems Incorporated and Bristol-Myers Squibb Company. ERBITUX product monograph. Branchburg, NJ, USA; March 2009.
52. Mayne Pharma (Canada) Inc. Cisplatin Package Insert. Montreal, QC; Undated.
53. Trissel LA. Handbook on Injectable Drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2003.
54. Repchinsky C editor. Cisplatin CPhA monograph, Compendium of Pharmaceuticals and Specialties. 12th ed. Ottawa, Ontario: Canadian Pharmacists Association; 2004.
55. Sandoz Canada Inc. Cisplatin Injection BP product monograph. Boucherville, Quebec; 13 April 2011.
56. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 September
2007.
57. Trissel LA. Handbook on Injectable Drugs. 16th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2011. p. 378.
58. Teva Canada Limited. Cisplatin injection product monograph. Toronto, Ontario; 6 March 2013.
59. Janssen-Ortho Inc. LEUSTATIN Product Monograph. Toronto, Ontario; 31 July 2006.
60. BC Cancer Agency Lymphoma Tumour Group. (LYCDA) BCCA Protocol Summary for Treatment of Hairy Cell Leukemia with Cladribine. Vancouver, British Columbia: BC Cancer
Agency; 1 February 2007.
61. Myrna O'Brodovich. Personal communication. Senior Medical Information Associate Ortho Biotech; 2 April 2008.
62. de Lemos ML, Hamata L. Stability issues of parenteral chemotherapy drugs. J Oncol Pharm Pract 2007;13(1):27-31.
63. Pharmaceutical Partners of Canada, Inc. Cladribine For Injection product monograph. Richmond Hill, Ontario; 27 November 2008.
64. Oryx Pharmaceuticals Inc. Clasteon Product Monograph. Mississauga, Ontario; 25 November 2004.
65. Baxter Corporation. Procytox Package Insert. Toronto, Ontario; 2004.
66. Baxter Corporation. Procytox Package Insert. Missisauga, Ontario; 1 October 2003.
67. Paul Agro. Personal communication. Medical Information, cyclophosphamide, Baxter. 12 July, 2006.
68. Hospira Healthcare Corporation. Cytarabine Injection product monograph. Saint-Laurent, Quebec; 25 November 2013.
69. BC Cancer Agency Miscellaneous Origin Tumour Group. (MOIT) BCCA Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine.
Vancouver, British Columbia: BC Cancer Agency; 1 May 2009.
70. My Dang, Regulatory Affairs Associate. Personal communication. Mayne Pharma (Canada) Inc.; 4 May 2007.
71. Abraxis Pharmaceutical Products. Dacarbazine product information package. Schaumburh, IL; December 2006.
72. Trissel L. Handbook on injectable drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 428-431.
73. Mayne Pharma (Canada) Inc. DACARBAZINE FOR INJECTION product monograph. Montreal, Quebec; 25 July 2003.
74. John Korontzis. Personal communication. Regulatory Affairs Associate, Dacarbazine, Mayne Pharma Canada; #FEB-14-2005 (february 8, 2005).
75. Recordati Rare Diseases Inc. COSMEGEN product monograph. Lebanon, New Jersey USA; 24 July 2014.
76. Andy Harbrow. Personal communication. Global Medical Services Manager, Primevigilance (for Recordati Rare Diseases Inc.); 15 July 2014.
77. Genentech Inc. DARZALEX full prescribing information. Horsham, PA, USA; Nov 2015.
78. Erfa Canada Inc. Daunorubicin injection product monograph. Westmount, Quebec; 6 December 2002.
79. Erfa Canada Inc. Material Safety Data Sheet. Montreal, Quebec; 3 October 2007.
80. Henri Knafo MD. Personal communication. Medical Director, Erfa Canada Inc; 14 July 2008.
81. Henri Knafo MD. Personal communication. Medical director, Erfa Canada Inc; 09 July 2008.
82. Novopharm Limited. Daunorubicin Package Insert. Toronto, Canada; Undated.

44/46
83. Ferring Pharmaceuticals. FIRMAGON product monograph. North York, Ontario; 20 March 2013.
84. Ferring Pharmaceuticals. FIRMAGON product monograph. North York, Ontario; 06 November 2009.
85. Amgen Canada Inc. XGEVA product monograph. Mississauga, Ontario; 14 October 2011.
86. Pfizer Canada Inc. ZINECARD product monograph. Kirkland, Quebec; 12 August 2010.
87. Hospira Healthcare Corporation. DOCETAXEL FOR INJECTION product monograph. Saint-Laurent, Quebec; 21 February 2011.
88. Hospira Canada Clinical Support Team. Personal communication. Hospira Canada Healthcare Corporation; 21 March 2011.
89. Josse Lloyd Senior Clinical Specialist. Email received March 12, 2013. Hospira Healthcare Corporation; 12 March 2013;.
90. Josee Lloyd, Senior Clinical Specialist. Subject : Docetaxel Injection 160mg/16mL and 80 mg/8mL multidosing and venting needles. Hospira Clinical Support Team; 13 July 2011.
91. sanofi-aventis Canada Inc. TAXOTERE product monograph. Laval, Quebec; 15 April 2011.
92. Walker S. Stability of docetaxel solution after Dilution in Ethanol and Storage in vials and after Dilution in Normal Saline and Storage in Bags. Can J Hosp Pharm 2007;60(4):231237.
93. Accord Healthcare Inc. Doxorubicin injection product monograph. Montreal, Quebec; 9 April 2014.
94. Mayne Pharma (Canada) Inc. Doxorubicin Package Insert. Montreal, QC; Undated.
95. Mayne Pharma (Canada) Inc. Doxorubicin Product Monograph. Montreal, Quebec; 2002.
96. Novopharm Limited. Doxorubicin Product Monograph. Scarborough, Ontario; 8 November 1996.
97. Pfizer Canada Inc. ADRIAMYCIN injection product monograph. Kirkland, Quebec; 28 August 2007.
98. Janssen Inc. CAELYX product monograph. Toronto, Ontario; 10 October 2013.
99. Novopharm. Epirubicin for Injection product monograph. Toronto, Ontario; 16 March 2009.
100. Pharmaceutical Partners of Canada, Inc. Epirubicin Hydrochloride Injection product monograph. Richmond Hill, Ontario; 6 July 2010.
101. Pharmacia Canada Inc. Pharmorubicin PFS Package Insert. Mississauga, Ontario; May 2003.
102. BC Cancer Agency Lymphoma Tumour Group. (ULYEPOCHR) Interim BCCA Protocol Summary for Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin,
VinCRIStine, Cyclophosphamide, PredniSONE, and riTUXimab (LYEPOCHR) with Intrathecal Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 1 July 2015.
103. Barry Goldspiel. Personal communication. NIH Clinical Centre; 14 April 2015.
104. Wolfe JL, Thoma LA, Du C, et al. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection. Am J Health-Syst
Pharm 1999;56:985-989.
105. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013;369:1915-1925.
106. Eisai Limited. HALAVEN product monograph. Mississauga, Ontario; 17 January 2013.
107. Bristol Laboratories of Canada. Vepesid Package Insert. Montreal, Canada; March 2000.
108. Nicole Hojm and Kinda Karra. Personal communication. Medical Information, etoposide, Bristol-Myers Squibb. February 2005.
109. The United States Pharmacopeial Convention, Inc. General Chapter 797 proposed revisions. ; 2006.
110. The United States Pharmacopeial Convention, Inc. General Chapter 51: Antimicrobial effectiveness testing. USP 28-NF 23. Rockville, Maryland: The United States
Pharmacopeial Convention, Inc.; 2004.
111. BC Cancer Agency. Provincial Pharmacy Directive III-50-04: Management of Particulate During Sterile Preparation. Vancouver, British Columbia: BC Cancer Agency; 9 July
2014.
112. Sandoz Canada Inc. Etoposide injection product monograph. Kirkland, Quebec; 27 February 2012.
113. Novopharm Limited. Etoposide Product Monograph. Toronto, Ontario; 2000.
114. Lepage R, Walker S, Godin J. Stability and compatibility of etoposide in normal saline. Canadian Journal of Hospital Pharmacy 2000;53(5):338-345.
115. The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United
States Pharmacopeial Convention, Inc.; 2003.
116. Angie Chan. Personal communication. Drug Information Pharmacist, Novopharm. 29 September 2006.
117. Bristol-Myers Squibb Company. ETOPOPHOS product monograph. Princeton, New Jersey, USA; March 2011.
118. Bristol-Myers Squibb Company. ETOPOPHOS product monograph. Princeton, New Jersey, USA; September 2013.
119. Amgen Canada Inc. NEUPOGEN product monograph. MIssissauga, Ontario; 21 March 2014.
120. Amgen Medical Information. Personal communication. Amgen Canada Inc.; 8 July 2014.
121. Trissel LA. Handbook on Injectable Drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc; 2005. p. 648-655.
122. Berlex Canada Inc. Fludara Package Insert. Lachine, Quebec; December 1998.

45/46
123. Trissel's2 Clinical Pharmaceutics Database (Parenteral Compatibility) [database on the internet]. Fludarabine. Thomson MICROMEDEX, Available at:
http://www.micromedex.com/. Accessed 14 September, 2007.
124. Novopharm Limited. Fludarabine product information package. Toronto, Ontario; 21 June 2007.
125. Accord Healthcare Inc. Fluorouracil injection product monograph. Kirkland, Quebec; 30 September 2013.
126. John Korontzis. Personal communication. Regulatory Affairs Associate, Fluorouracil, Mayne Pharma Canada; reference # FEB-43-2005.February 16, 2005.
127. BC Cancer Agency Experimental Therapeutics. Physicochemical stability analysis of fluorouracil products in final chemotherapeutic preparations.Vancouver, BC. 19 August
2011;Study number 50009:1-43.
128. Stiles ML, Allen Jr LV, Tu YH. Stability of fluorouracil administered through four portable infusion pumps. American Journal of Hospital Pharmacy 1989;46(10):2036-2040.
129. Mayne Pharma (Canada) Inc. Fluorouracil Package Insert. Montreal, Quebec; Undated.
130. Sandoz Canada Inc. Fluorouracil Injection product monograph. Boucherville, Quebec; 3 April 2012.
131. Accord Healthcare Inc. Gemcitabine injection product monograph. Kirkland, Quebec; 29 September 2014.
132. Astron Research LTD. UK. Gemcitabine for Injection (STBRG/ACGEM/01) Stability Study Report (Dilution Study) 2001.
133. Purvi Agrawal BPharm (Regulatory Affairs Manager). Personal communication. Accord Healthcare Inc.; 07 September 2012.
134. Eli Lilly Canada Inc. Gemzar Package Insert. Toronto, Ontario; 16 January 2002.
135. Marilyn Bain BSc N. Personal communication. Sr Therapeutic Area Specialist Medical Information, Gemzar. September 2004.
136. Hospira Healthcare Corporation. Gemcitabine Injection product monograph. Montreal, QC; 27 February 2013.
137. Hospira Healthcare Corporation. Gemcitabine for injection, USP product monograph. Montreal, Quebec; 3 November 2008.
138. Rose Toussaint. Personal communication. Clinical Specialist, Hospira Canada Healthcare Corporation; 26 May2009.
139. Hospira Canada Clinical Support Team. Personal communication. Hospira Healthcare Corporation; 13 March 2009.
140. Novopharm Limited. Gemcitabine product monograph. Toronto, Ontario; 08 February 2008.
141. Sandoz Standard. Gemcitabine for injection product monograph. Boucherville, Quebec; 13 November 2007.
142. Amelie Fontaine B.Sc (N). Personal communication. Drug Information Specialist, Sandoz (vial); 9 April 2009.
143. Stephane Jean. Personal communication. Drug Information Specialist; Sandoz Canada; 7 May 2008.
144. Stephane Jean. Personal communication. Drug Information Specialist, Sandoz Canada; 25 September 2009.
145. Amelie Fontaine B.Sc (N). Personal communication. Drug Information Specialist, Sandoz (infusion); 9 April 2009.
146. Pfizer Canada Inc. IDAMYCIN product monograph. Kirkland, Quebec; 19 February 2009.
147. Pharmaceutical Partners of Canada, Inc. IDARUBICIN HYDROCHLORIDE INJECTION product monograph. Richmond Hill, Ontario; 12 November 2009.
148. Baxter Corporation. IFEX product monograph. Mississauga, Ontario; 5 April 2012.
149. Pharmaceutical Partners of Canada, Inc. Ifosfamide for Injection product monograph. Richmond Hill, Ontario; 17 January 2008.
150. sanofi-aventis Canada. Iniparib (BSI-201;SAR240550) Special Access Program Guidance for the Physician. Laval, Quebec; 15December2010.
151. Merck Canada Inc. INTRON A product monograph. Kirkland, Quebec; 13 March 2015.
152. Edward Kavalec BSc(Pharm), Medical Services Specialist. Personal communication. Merck Canada Inc. Medical Information; 1 April 2015.
153. Bristol Myers Squibb Canada. YERVOY product monograph. Montreal, Quebec; 1 February 2012.
154. Accord Healthcare Inc. Irinotecan injection product monograph. Kirkland, Quebec; 6 May 2014.
155. Mayne Pharma (Canada) Inc. Irinotecan Package Insert. Montreal, Quebec; 28 April 2005.
156. Beryl Chan. Personal communication. Mayne Pharma (Canada) Inc. Scientific Affairs Manager, Irinotecan. 2 February 2006.
157. Walker S, Iazzetta J, Law S. Irinotecan stability in vials following puncture when stored at 23c or 4c. Can J Hosp Pharm 2006;59 (Suppl 2):36.
158. Pharmacia Canada Inc. Camptosar Package Insert. Mississauga, Ontario; May 2002.
159. Sandoz Canada Inc. Irinotecan injection package insert. Boucherville, Quebec; April 2008.
160. Bristol-Myers Squibb. IXEMPRA product monograph. Princeton, New Jersey; 01 October 2007.
161. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5.

46/46

Chemo Stability Chart AtoK 1jun2016

Transféré par

Informations du document

Titre original

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

Chemo Stability Chart AtoK 1jun2016

Transféré par

Droits d'auteur :

Formats disponibles

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

DRUG & STRENGTH

- do not use in-line

direct diluent against

Less than 30 mcg/mL:

filter NOT required6

discard at the end of

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

2550 mL* NS only10

(use filter needle to

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

do not shake; rotate

do not shake; mix

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

- contact with the

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

do not shake; roll to

transfer from vial to

allow to stand for a

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

50 mL* NS, SWI31

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

0.4-1.8 mg/mL in NS,

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

use 5-micron nylon

0.10 0.26 mg/mL

slowly direct diluent

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

- infusion lines may

swirl gently; do not

3.3 mg/mL in 10%

diluent to reach RT,

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Less than or equal to

Greater than 60 mg:

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Less than or equal to

Greater than 60 mg:

Less than or equal to

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

48h F, end of day

Do NOT use D5W59

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Do NOT use D5W

BC Cancer Agency Chemotherapy Preparation and Stability Chart version 2.00

BC CANCER AGENCY CHEMOTHERAPY PREPARATION AND STABILITY CHART

Less than or equal to